Skip to main
AORT

Artivion (AORT) Stock Forecast & Price Target

Artivion (AORT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artivion is a leading player in the cardiovascular medical devices and technology market, with a strong portfolio of products targeting aortic disease and a presence in key markets such as North America, EMEA, and APAC. The company has a positive growth outlook, driven by new product launches and international expansion, and is expected to see sustained revenue growth of 8-12% in the coming years. While faced with competition and regulatory risks, Artivion's strong product mix and continued investment in R&D and expansion efforts can support solid margin improvement.

Bears say

Artivion is facing a slight setback and a slowdown in revenues due to barriersto adoption and upfront costs associated with its AMDS graft product. However, the company is taking steps to improve these issues and has a robust pipeline in place for future growth opportunities. Additionally, the recent acquisition of Endospan and its PMA approved aortic stent product indicates potential for long-term growth. While a slight adjustment in revenue and earnings estimates is warranted, the stock still remains an attractive investment with solid fundamentals and strong potential for margin and EBITDA growth.

Artivion (AORT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artivion (AORT) Forecast

Analysts have given Artivion (AORT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Artivion (AORT) has a Strong Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artivion (AORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.